Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications “i was trying do maths” exploring impact risk communication discrete choice experiments
… where you’ll learn: Health Technology Assessment: How do HTA bodies define rare or ultra-orphan diseases? How do HTA bodies appraise rare disease drugs? What are the key … challenges to developing cost-effectiveness models? How do we overcome these HTA economic modelling challenges? …
… be reconciled on occasions when they were discrepant. It was used as the methodological framework of choice to generate evidence on the safety and efficacy of … decisions. Related Services Pharmacoepidemiology and Risk Management Staff Members Julia Vila Guilera Xabier …
Services You must make critical decisions in today’s complex, competitive, and highly regulated pharmaceutical, medical device, and diagnostics industry. However, often, the knowledge needed to make good clinical, market access, and safety decisions isn’t …
… group and for MenB. Health Disparities To determine the impact of health disparities and suboptimal meningococcal … vaccination – adolescents and young adults are at risk for under-immunization, especially those with health … among healthcare professionals. One study limitation was the lack of studies containing specific marginalized …
… of expertise is survey design, cost-benefit analysis, and discrete-choice modeling. …
… Conference. Updated cost-utility and public health impact of recombinant zoster vaccine (RZV) in Canadians aged … and older. George S, Carrico J, Hicks K, Loukov D, Kaan I, Ng C, Regan J, Giannelos N. Cost-effectiveness and public … Canada. George S, Carrico J, Hicks K, Loukov D, Ng C, Kaan I, Curran D. …
… submissions. Prior to joining RTI-HS, he worked on a discrete-choice experiment with Queensland University of Technology in … violence prevention program in 2022. Mr. Bhogal was also a Pharmacy Manager for Boots UK. …
Gene Therapy Keep your gene therapy development on track The paradigm of regenerative medicine development is changing. Expedited regulatory approvals can help developers, but only if they are timely with strategic planning and fully versed in the latest …
… indicated that between 2007 and 2013, there was an increase in the number of trials that use a patient … drug development and has issued new guidelines on how to do so. At the same time, the health care industry has …
… Infectious Diseases (ESPID). Comparing the public health impact of switching to pediatric 13-valent pneumococcal … - Abstract Number: 384 Comparing the public health impact of the pediatric 15- and 20-valent pneumococcal …